CA2406213A1 - Compositions et procedes de traitement et de diagnostic du cancer du sein - Google Patents

Compositions et procedes de traitement et de diagnostic du cancer du sein Download PDF

Info

Publication number
CA2406213A1
CA2406213A1 CA002406213A CA2406213A CA2406213A1 CA 2406213 A1 CA2406213 A1 CA 2406213A1 CA 002406213 A CA002406213 A CA 002406213A CA 2406213 A CA2406213 A CA 2406213A CA 2406213 A1 CA2406213 A1 CA 2406213A1
Authority
CA
Canada
Prior art keywords
seq
polynucleotide
cdna sequence
sequence
determined cdna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002406213A
Other languages
English (en)
Inventor
Yuqiu Jiang
Davin C. Dillon
Jennifer L. Mitcham
Jiangchun Xu
Susan L. Harlocker
William T. Hepler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corixa Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/551,621 external-priority patent/US6844325B2/en
Priority claimed from US09/604,287 external-priority patent/US6586572B2/en
Application filed by Individual filed Critical Individual
Publication of CA2406213A1 publication Critical patent/CA2406213A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/924—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis using nanostructure as support of dna analysis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte sur des compositions et procédés de traitement et de diagnostic de cancers tels que le cancer du sein. Lesdites compositions comprennent une ou plusieurs protéines de tumeurs du sein, de leurs parties immunogènes et les polynucléotides codant pour lesdites parties. En variante, la composition thérapeutique peut comporter une cellule portant un antigène exprimant une protéine tumorale ou une cellule T spécifique de cellules exprimant ladite protéine. Ces compositions peuvent par exemple servir à la prévention et au traitement de maladies telles que le cancer du sein. L'invention porte également sur des méthodes de diagnostic basées sur la détection dans un prélèvement, d'une protéine de tumeurs du sein ou de l'ARNm codant pour elle.
CA002406213A 2000-04-17 2001-04-12 Compositions et procedes de traitement et de diagnostic du cancer du sein Abandoned CA2406213A1 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US09/551,621 US6844325B2 (en) 1998-12-28 2000-04-17 Compositions for the treatment and diagnosis of breast cancer and methods for their use
US09/551,621 2000-04-17
US09/590,751 US6756477B1 (en) 1998-12-28 2000-06-08 Compositions and methods for the therapy and diagnosis of breast cancer
US09/590,751 2000-06-08
US09/604,287 2000-06-22
US09/604,287 US6586572B2 (en) 1998-12-28 2000-06-22 Compositions and methods for the therapy and diagnosis of breast cancer
US09/620,405 US6528054B1 (en) 1998-12-28 2000-07-20 Compositions and methods for the therapy and diagnosis of breast cancer
US09/620,405 2000-07-20
PCT/US2001/012164 WO2001079286A2 (fr) 2000-04-17 2001-04-12 Compositions et procedes de traitement et de diagnostic du cancer du sein

Publications (1)

Publication Number Publication Date
CA2406213A1 true CA2406213A1 (fr) 2001-10-25

Family

ID=27504757

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002406213A Abandoned CA2406213A1 (fr) 2000-04-17 2001-04-12 Compositions et procedes de traitement et de diagnostic du cancer du sein

Country Status (14)

Country Link
US (1) US6528054B1 (fr)
EP (1) EP1299417A2 (fr)
JP (1) JP5053497B2 (fr)
CN (1) CN1646563A (fr)
AU (1) AU2001255369A1 (fr)
BR (1) BR0110091A (fr)
CA (1) CA2406213A1 (fr)
HU (1) HUP0301740A2 (fr)
MX (1) MXPA02010244A (fr)
NO (1) NO20024972L (fr)
NZ (1) NZ521865A (fr)
PL (1) PL365244A1 (fr)
RU (1) RU2344831C2 (fr)
WO (1) WO2001079286A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2736163C1 (ru) * 2019-05-29 2020-11-12 Федеральное Государственное бюджетное образовательное учреждение высшего образования Дагестанский государственный медицинский университет Министерства здравоохранения Российской Федерации Даггосмедуниверситет Способ интраоперационной диагностики рака молочной железы

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033230A1 (en) * 1997-12-24 2004-02-19 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US7414112B2 (en) * 1998-10-08 2008-08-19 Genentech, Inc. Antibodies to PRO1550 polypeptides
US6969518B2 (en) * 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US7598226B2 (en) * 1998-12-28 2009-10-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6893818B1 (en) 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
WO2001040269A2 (fr) * 1999-11-30 2001-06-07 Corixa Corporation Compositions et methodes destinees au traitement et au diagnostic du cancer du sein
US7354992B2 (en) * 1999-11-30 2008-04-08 Ludwig Institute For Cancer Research Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof
GB0222787D0 (en) * 2002-10-02 2002-11-06 Univ Liverpool Metastasis inducing compounds
US20060241051A1 (en) 2002-12-26 2006-10-26 Chieko Kitada Metastin derivatives and use thereof
US20070178532A1 (en) * 2003-03-24 2007-08-02 The Gov.Of The Us As Represented By The Secretary Identification, quantification, and characterization of t cells and t cell antigens
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
AR049938A1 (es) 2004-06-25 2006-09-13 Takeda Pharmaceutical Derivados de metastina y utilizacion de los mismos
KR101772375B1 (ko) * 2005-09-07 2017-08-29 신라젠(주) Ｇｍ-ｃｓｆ를 발현하는 폭스바이러스를 사용한 전이성 및/또는 전신 파종성 암의 전신 치료법
US20100029504A1 (en) * 2007-01-16 2010-02-04 Phigenix, Inc. Detecting pax2 for the diagnosis of breast cancer
US8404643B2 (en) 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
TWI386417B (zh) 2005-12-22 2013-02-21 Takeda Pharmaceutical 轉移抑素衍生物及其用途
WO2008039482A2 (fr) * 2006-09-26 2008-04-03 The Regents Of The University Of California Méthodes et compositions pour la prévention et le traitement du cancer
US9517240B2 (en) 2006-09-26 2016-12-13 The Regents Of The University Of California Methods and compositions for cancer prevention and treatment
TWI404726B (zh) 2006-10-25 2013-08-11 Takeda Pharmaceutical 腫瘤轉移抑制素衍生物及其用途
CN101974088B (zh) * 2010-11-03 2014-04-02 中国人民解放军军事医学科学院基础医学研究所 乳腺珠蛋白单克隆抗体及其在乳腺癌诊断中的应用
WO2013016126A1 (fr) 2011-07-22 2013-01-31 The General Hospital Corporation Nanoparticules thérapeutiques et procédés d'utilisation de celles-ci
JP2016214239A (ja) * 2015-05-15 2016-12-22 国立大学法人高知大学 膵がんマーカー
KR102802241B1 (ko) * 2015-12-04 2025-05-07 베링거 인겔하임 인터내셔날 게엠베하 종양 세포에서 wnt 신호 전달을 길항하는 바이파라토픽 폴리펩타이드
US20190016821A1 (en) * 2016-01-08 2019-01-17 Temple University Of The Commonwealth System Of Higher Education Stabilized peptide fragments from protocadherin fat1 as cancer biomarkers
AU2018349387B2 (en) 2017-10-12 2022-05-19 E&S Healthcare Co., Ltd. Thioredoxin 1 epitope and monoclonal antibody specifically binding thereto
TWI709188B (zh) 2018-09-27 2020-11-01 財團法人工業技術研究院 基於機率融合的分類器、分類方法及分類系統
CN112724233B (zh) * 2019-10-28 2023-09-26 中国医学科学院药物研究所 一种角蛋白bd-13、制法和其药物组合物与用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2613988A (en) 1988-01-04 1989-08-01 E.I. Du Pont De Nemours And Company Multiple stage affinity process for isolation of specific cells from a cell mixture
US5215926A (en) 1988-06-03 1993-06-01 Cellpro, Inc. Procedure for designing efficient affinity cell separation processes
WO1991016116A1 (fr) 1990-04-23 1991-10-31 Cellpro Incorporated Dispositif et procede d'immunoselection
JP3040469B2 (ja) 1990-10-18 2000-05-15 セルプロ インコーポレイテッド 可撓性容器を用いて粒子を分離する装置及び方法
US5240856A (en) 1991-10-23 1993-08-31 Cellpro Incorporated Apparatus for cell separation
EP1505159B1 (fr) 1995-03-17 2008-05-28 John Wayne Cancer Institute Dépistage des métastases dans le sein à l'aide d'un titrage par marqueurs multiples
US5922836A (en) 1995-05-31 1999-07-13 Washington University Mammaglobin antigens
US5668267A (en) 1995-05-31 1997-09-16 Washington University Polynucleotides encoding mammaglobin, a mammary-specific breast cancer protein
EP0846172A2 (fr) * 1995-08-16 1998-06-10 The President And Fellows Of Harvard College Technique d'identification des genes provoquant la non-disjonction des chromosomes
US5986170A (en) 1995-11-13 1999-11-16 Corixa Corporation Murine model for human carcinoma
US5891857A (en) 1996-02-20 1999-04-06 Vanderbilt University Characterized BRCA1 and BRCA2 proteins and screening and therapeutic methods based on characterized BRCA1 and BRCA2 proteins
WO1998021331A1 (fr) 1996-11-12 1998-05-22 Incyte Pharmaceuticals, Inc. Proteines humaines specifiques de tumeur du sein
JP2001509664A (ja) 1997-02-03 2001-07-24 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド 乳ガン特異的遺伝子１
CA2291260A1 (fr) 1997-06-06 1998-12-10 Human Genome Sciences, Inc. 207 proteines secretees par l'etre humain
EP1005544A4 (fr) 1997-08-19 2004-07-14 Human Genome Sciences Inc 70 proteines secretees humaines
CA2316397A1 (fr) * 1997-12-24 1999-07-08 Corixa Corporation Composes destines a l'immunotherapie et au diagnostic du cancer du sein, et leur mode d'utilisation
JP2002533056A (ja) * 1998-03-18 2002-10-08 コリクサ コーポレイション 肺癌の治療および診断のための化合物および方法
CN100419079C (zh) * 1998-07-14 2008-09-17 科里克萨有限公司 用于治疗和诊断前列腺癌的组合物和方法
WO2000008210A1 (fr) 1998-08-04 2000-02-17 Diadexus Llc Nouvelle methode permettant de diagnostiquer, de surveiller le cancer du sein, d'en determiner le stade ainsi que d'en former des images et de le traiter
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
DE60044119D1 (de) 1999-01-21 2010-05-20 Abbott Lab Reagentien und verfahren zur erkennung von erkrankungen der brust
EP1259812A2 (fr) 1999-05-28 2002-11-27 Ludwig Institute For Cancer Research Antigenes associes au cancer du sein, de la prostate et de l'estomac et leur utilisation
CA2390802A1 (fr) 1999-11-23 2001-05-31 Diadexus, Inc. Nouvelle methode de diagnostic, de surveillance, de stadification, d'imagerie et de traitement du cancer du sein
WO2001047959A2 (fr) 1999-11-30 2001-07-05 Ludwig Institute For Cancer Research Molecules d'acides nucleiques isoles codant pour des antigenes associes au cancers, ces antigenes et leur utilisation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2736163C1 (ru) * 2019-05-29 2020-11-12 Федеральное Государственное бюджетное образовательное учреждение высшего образования Дагестанский государственный медицинский университет Министерства здравоохранения Российской Федерации Даггосмедуниверситет Способ интраоперационной диагностики рака молочной железы

Also Published As

Publication number Publication date
WO2001079286A3 (fr) 2003-01-30
AU2001255369A1 (en) 2001-10-30
HUP0301740A2 (hu) 2004-06-28
RU2002130715A (ru) 2004-03-27
NO20024972L (no) 2002-12-11
US6528054B1 (en) 2003-03-04
MXPA02010244A (es) 2003-05-23
BR0110091A (pt) 2004-02-25
EP1299417A2 (fr) 2003-04-09
NO20024972D0 (no) 2002-10-16
JP5053497B2 (ja) 2012-10-17
RU2344831C2 (ru) 2009-01-27
WO2001079286A2 (fr) 2001-10-25
CN1646563A (zh) 2005-07-27
NZ521865A (en) 2004-07-30
JP2004520802A (ja) 2004-07-15
PL365244A1 (en) 2004-12-27

Similar Documents

Publication Publication Date Title
US6579973B1 (en) Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6528054B1 (en) Compositions and methods for the therapy and diagnosis of breast cancer
US20030166022A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer
US6680197B2 (en) Compositions and methods for the therapy and diagnosis of breast cancer
US6756477B1 (en) Compositions and methods for the therapy and diagnosis of breast cancer
CA2380873A1 (fr) Compositions et techniques de therapie et de diagnostic du cancer du poumon
CZ20023567A3 (cs) Sloučeniny a způsoby pro terapii a diagnostiku karcinomu plic
US6586572B2 (en) Compositions and methods for the therapy and diagnosis of breast cancer
US6590076B1 (en) Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6518237B1 (en) Compositions for treatment and diagnosis of breast cancer and methods for their use
US20030023036A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer
US6573368B2 (en) Compositions for the treatment and diagnosis of breast cancer and methods for their use
US20020068288A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
US20020150581A1 (en) Compositions and methods for the therapy and diagnosis of breast cancer
JP2002540789A5 (fr)
US20020048759A1 (en) Compositions and methods for the therapy and diagnosis of ovarian and endometrial cancer
US20020072503A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
HK1081208A (en) Compostions and methods for hte therapy and diagnosis of breast cancer
AU2006201363A1 (en) Compositions for the treatment and diagnosis of breast cancer and methods for their use
JP2002507425A (ja) セリンプロテアーゼであるヒトｃａｓｂ１２ポリペプチド
JP2003526320A (ja) 複数の腫瘍において過剰発現される抗原ｃａｓｂ４１４
US20020142957A1 (en) Compositions and methods for the therapy and diagnosis of colon cancer
US20020102679A1 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
US20030194764A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
US20020123619A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20131230